Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Cited by (1,002)

Items 101–200 of 1,002

1. Progress in understanding the molecular pathogenesis of human lung cancer
   Yoshitaka Sekido, Kwun Meng Fong, John Dorrance Minna · 1998 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
2. In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy
   Régis Masson, Olivier Lefèbvre, Agnès Noël, Elmostafa El Fahime, Marie‐Pierre Chenard, Corinne Wendling, Florence Kebers, Marianne LeMeur, Andrée Dierich, Jean‐Michel Foidart et al. · 1998 · The Journal of Cell Biology
3. Molecular targets for breast cancer therapy and prevention
   Johannes Bange, Esther Zwick, Axel Ullrich · 2001 · Nature Medicine
4. Phage display screening of therapeutic peptide for cancer targeting and therapy
   Phei Er Saw, Erwei Song · 2019 · Protein & Cell
5. Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
   Roy S. Herbst, Kenneth R. Hess, Hai Thanh Tran, Jennifer E. Tseng, Nizar A. Mullani, Chusilp Charnsangavej, Timothy L. Madden, Darren W. Davis, David James McConkey, Michael S. O’Reilly et al. · 2002 · Journal of Clinical Oncology
6. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis
   Johan Dixelius, Helena Elding Larsson, Takako Sasaki, Kristina Holmqvist, Lingge Lu, Åke Engström, Rupert Timpl, Michael Welsh, Lena Claesson · 2000 · Blood
7. Angiogenesis in myelodysplastic syndromes
   Giancarlo Pruneri, Francesco Bertolini, Davide A. Soligo, Nadia Carboni, Agostino Cortelezzi, Pier Francesco Ferrucci, Roberto Buffa, Giorgio Lambertenghi‐Deliliers, Francesco Pezzella · 1999 · British Journal of Cancer
8. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
   Calvin Jay Kuo, Filip A. Farnebo, Evan Y. Yu, Rolf H. B. Christofferson, Rebecca A. Swearingen, Robert Carter, Horst A. von Recum, Jenny Yuan, Junne Kamihara, Evelyn A. Flynn et al. · 2001 · Proceedings of the National Academy of Sciences
9. Clinical Experience with Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers
   Lee S. Rosen · 2002 · Cancer Control
10. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis
    Sepi Mahooti, Joseph A. Madri · 1998 · Journal of Cell Science
11. Angiogenesis Research: Guidelines for Translation to Clinical Application
    Timothy D. Browder, Jan E.W. Palmblad, Judah Folkman · 2001 · Thrombosis and Haemostasis
12. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
    Aaron J. Schueneman, Eric A. Himmelfarb, Ling Geng, Jiahuai Tan, Edwin F. Donnelly, Dirk B. Mendel, Gerald McMahon, Dennis E. Hallahan · 2003 · PubMed
13. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
    Hubing Shi, Yujie Huang, Hao Zhou, Xiaomin Song, Shaopeng Yuan, Yan Fu, Yongzhang Luo · 2007 · Blood
14. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.
    Oliver Kisker, Cord Michael Becker, Daniela Prox, Michael W. Fannon, Robert J. D’Amato, Evelyn A. Flynn, W E Fogler, B. Kim Lee Sim, Elizabeth N. Allred, Steven Robert Pirie-Shepherd et al. · 2001 · PubMed
15. Inhibition of Angiogenesis by Interleukin 4
    Olga V. Volpert, Tim Fong, Alisa Erika Koch, Jeffrey D. Peterson, Carl R. Waltenbaugh, Robert I. Tepper, Noël Bouck · 1998 · The Journal of Experimental Medicine
16. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
    Chikezie O. Madu, Stephanie Y. Wang, Chinua O. Madu, Yi Wei Lu · 2020 · Journal of Cancer
17. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.
    Stéphanie Filleur, Aurélie Courtin, Slimane Ait‐Si‐Ali, Julien Guglielmi, Carole Arnold, Annick Harel‐Bellan, Philippe Clézardin, Florence Cabon · 2003 · PubMed
18. Proinflammatory functions of vascular endothelial growth factor in alloimmunity
    Reinders, Marlies E.J., Sho, Masayuki, Izawa, Atsushi, Wang, Ping, Mukhopadhyay, Debabrata, Koss, Kerith E., Geehan, Christopher S., Luster, Andrew D., Sayegh, Mohamed H., Briscoe, David M. · 2003 · Journal of Clinical Investigation
19. Cytosolic drug delivery using pH- and light-sensitive liposomes
    Oleg V. Gerasimov, Jeremy A. Boomer, Marquita M. Qualls, David H. Thompson · 1999 · Advanced Drug Delivery Reviews
20. Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
    Leonard B. Kaban, John Butler Mulliken, R. Alan B. Ezekowitz, D Phil, David H. Ebb, Peter S. Smith, Judah Folkman · 1999 · PEDIATRICS
21. Metronomic scheduling: the future of chemotherapy?
    Giampietro Gasparini · 2001 · The Lancet Oncology
22. CEA-Related Cell Adhesion Molecule 1
    Süleyman Ergün, Nerbil Kilic, Gudrun Ziegeler, Arne Hansen, Peter Nollau, Julica Götze, Jan‐Henner Wurmbach, Andrea Kristina Horst, Joachim Weil, Malkanthi Fernando et al. · 2000 · Molecular Cell
23. Targeted Molecular Therapy of GBM
    Paul S. Mischel, Timothy Francis Cloughesy · 2003 · Brain Pathology
24. Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches
    Harman Talat Saman, Syed Shadab Raza, Shahab Uddin M.S., Kakil Ibrahim Rasul · 2020 · Cancers
25. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Giannoula Lakka Klement, Ping Hsin Huang, Barbara Mayer, Shane K. Green, Shan Man, Peter Böhlen, Daniel J. Hicklin, Robert S. Kerbel · 2002 · PubMed
26. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily
    Joseph P. Eder, Jeffrey G. Supko, Jeffrey William Clark, Thomas A. Puchalski, Rocio García‐Carbonero, David P. Ryan, Lawrence N. Shulman, JoAnn Proper, Moira Kirvan, Barbara P. Rattner et al. · 2002 · Journal of Clinical Oncology
27. Tumor Vessel Development and Maturation Impose Limits on the Effectiveness of Anti-Vascular Therapy
    Michael Stanley Gee, William N. Procopio, Sosina Makonnen, Michael D. Feldman, Newman M. Yeilding, William M. F. Lee · 2003 · American Journal Of Pathology
28. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma.
    Mohanraj Dhanabal, Ramani Ramchandran, Ruediger Volk, Isaac Ely Stillman, Michelle Lombardo, M. Luisa Iruela‐Arispe, Michael Simons, Vikas P. Sukhatme · 1999 · PubMed
29. New functional roles for non-collagenous domains of basement membrane collagens
    Nathalie Ortéga, Zena Werb · 2002 · Journal of Cell Science
30. Molecular angiogenesis
    Michael Klagsbrun, Marsha A. Moses · 1999 · Chemistry & Biology
31. Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
    Robert S. Kerbel, Joanne Yu, Jennifer Tran, Shan Man, Alicia Viloria‐Petit, Giannoula Lakka Klement, Brenda Lynn Coomber, Janusz W. Rak · 2001 · Cancer and Metastasis Reviews
32. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis
    Mamoru Fujita, Izumi Hayashi, Shohei Yamashina, Moritoshi Itoman, Masataka Majima · 2002 · Biochemical and Biophysical Research Communications
33. Integrins as attractive targets for cancer therapeutics
    Meng Li, Ying Wang, Mengwei Li, Xuezhen Wu, Sarra Setrerrahmane, Hanmei Xu · 2021 · Acta Pharmaceutica Sinica B
34. Endogenous angiogenesis inhibitors and their therapeutic implications
    Yumei Cao · 2001 · The International Journal of Biochemistry & Cell Biology
35. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.
    Yumi Yokoyama, Mohanraj Dhanabal, Arjan W. Griffioen, Vikas P. Sukhatme, Sundaram Ramakrishnan · 2000 · PubMed
36. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis
    Dongfang Liu, Zachary H. Shriver, Ganesh Venkataraman, Yosuf El Shabrawi, Ram Sasisekharan · 2002 · Proceedings of the National Academy of Sciences
37. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
    Bernhard V. Sauter, Olivier Martinet, Weijian Zhang, John Mandeli, Savio L.C. Woo · 2000 · Proceedings of the National Academy of Sciences
38. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
    Stephen B. Fox, Giampietro Gasparini, Adrian Llewellyn Harris · 2001 · The Lancet Oncology
39. Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
    Frank A. Scappaticci · 2002 · Journal of Clinical Oncology
40. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
    Alexander H. R. Varey, E S Rennel, Yan Qiu, Heather S. Bevan, R. M. Perrin, S Raffy, AR Dixon, C Paraskeva, O Zaccheo, Andrew Bassim Hassan et al. · 2008 · British Journal of Cancer
41. Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
    James P. Thomas, Rhoda Z. Arzoomanian, Dona B. Alberti, Rebecca Marnocha, Fred Lee, Andreas Friedl, Kendra D. Tutsch, Amy Dresen, Peter G. Geiger, James M. Pluda et al. · 2003 · Journal of Clinical Oncology
42. Forty-Year Journey of Angiogenesis Translational Research
    Yihai Cao, Jack L. Arbiser, Robert J. D’Amato, Patrìcia A. D'Amore, Donald E. Ingber, Robert S. Kerbel, Michael Klagsbrun, Sharon Lim, Marsha A. Moses, Bruce R. Zetter et al. · 2011 · Science Translational Medicine
43. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity
    Takako Sasaki, Helena Elding Larsson, Dominic Tisi, Lena Claesson, Erhard Hohenester, Rupert Timpl · 2000 · Journal of Molecular Biology
44. Angiogenesis, lymphangiogenesis, and melanoma metastasis
    Michael Streit, Michael J. Detmar · 2003 · Oncogene
45. Targeting the tumor microenvironment
    Paraic A. Kenny · 2007 · Frontiers in bioscience
46. Doxorubicin gradients in human breast cancer.
    Jan Lankelma, H Dekker, Rafael Fernández Luque, S Luykx, Klaas Hoekman, Paul van der Valk, P. J. van Diest, Herbert M. Pinedo · 1999 · PubMed
47. Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased Vascularity
    Lars Göran Lundberg, Richard Lerner, Pär Sundelin, Rick A. Rogers, Judah Folkman, Jan E.W. Palmblad · 2000 · American Journal Of Pathology
48. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin
    Takako Sasaki, Helena Elding Larsson, Johan Kreuger, Markku Salmivirta, Lena Claesson, Ulf Lindahl, Erhard Hohenester, Rupert Timpl · 1999 · The EMBO Journal
49. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution
    Erhard Hohenester, Takako Sasaki, Bjorn Reino Olsen, Rupert Timpl · 1998 · The EMBO Journal
50. Interleukin‐18 acts as an angiogenesis and tumor suppressor
    Renhai Cao, Jacob Farnebo, Masashi Kurimoto, Yihai Cao · 1999 · The FASEB Journal
51. Targeting tumour vasculature: the development of combretastatin A4
    Jeremy Griggs, James C. Metcalfe, Robin Hesketh · 2001 · The Lancet Oncology
52. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.
    Daniel J. Price, Tihomir Miralem, Shuxian Jiang, R Steinberg, Hava Karsenty Avraham · 2001 · PubMed
53. Antiangiogenesis signals by endostatin
    Masayoshi Shichiri, Yukio Hirata · 2001 · The FASEB Journal
54. The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward
    Mark W. Kieran, Raghu Kalluri, Yoon‐Jae Cho · 2012 · Cold Spring Harbor Perspectives in Medicine
55. Near-infrared fluorescent imaging of tumor apoptosis.
    Alexander Petrovsky, Eyk A. Schellenberger, Lee Josephson, Ralph Weissleder, Alexei A. Bogdanov Jr · 2003 · PubMed
56. Wnt/?-catenin-pathway as a molecular target for future anti-cancer therapeutics
    Susanne Dihlmann, Magnus von Knebel Doeberitz · 2004 · International Journal of Cancer
57. Notch Activation during Endothelial Cell Network Formation in Vitro Targets the Basic HLH Transcription Factor HESR-1 and Downregulates VEGFR-2/KDR Expression
    Kevin L. Taylor, April.M. Henderson, Christopher C.W. Hughes · 2002 · Microvascular Research
58. Antiangiogenic gene therapy
    Judah Folkman · 1998 · Proceedings of the National Academy of Sciences
59. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999)
    Alberto d’Onofrio, Alberto Gandolfi · 2004 · Mathematical Biosciences
60. A systematic review on ethnomedicines of anti-cancer plants
    Akash Tariq, Sehrish Sadia, Kaiwen Pan, Ihteram Ullah, Sakina Mussarat, Feng Sun, Olusanya Abiodun Olatunji, Batbaatar Altanzagas, Zilong Li, Dagang Song et al. · 2017 · Phytotherapy Research
61. Endogenous inhibitors of angiogenesis
    Ribatti, Domenico · 2009 · Leukemia Research
62. Cancer: looking outside the genome
    Judah Folkman, Philip Hahnfeldt, Lynn Hlatky · 2000 · Nature Reviews Molecular Cell Biology
63. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo
    Yu Bai, Qiqi Mao, Jie Qin, Xiangyi Zheng, Yun‐Bin Wang, Kai Ge Yang, Huafeng Shen, Liping Xie · 2009 · Cancer Science
64. A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α v β 3 ) Antibody in Patients with Metastatic Cancer
    James A. Posey, M.B. Khazaeli, Alma Delgrosso, Mansoor Noorali Saleh, Chin‐Yu Lin, William D. Huse, Albert F. LoBuglio · 2001 · Cancer Biotherapy and Radiopharmaceuticals
65. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin‐like growth factor binding protein‐3
    Rana Pratap Singh, Anil K. Tyagi, Sivanandhan Dhanalakshmi, Rajesh Agarwal, Chapla Agarwal · 2003 · International Journal of Cancer
66. Cloning, Expression, andin VitroActivity of Human Endostatin
    Mohanraj Dhanabal, Ruediger Volk, Ramani Ramchandran, Michael Simons, Vikas P. Sukhatme · 1999 · Biochemical and Biophysical Research Communications
67. Suppression of angiogenesis and tumor growth by the inhibitor K1–5 generated by plasmin-mediated proteolysis
    Renhai Cao, Hua‐Lin Wu, Niina Veitonmäki, Philip Aaron Linden, Jacob Farnebo, Guey-Yueh Shi, Yihai Cao · 1999 · Proceedings of the National Academy of Sciences
68. Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
    Amit Walia, Jessica Yang, Yu-Hui Huang, Mark I. Rosenblatt, Jin‐Hong Chang, Dimitri T. Azar · 2015 · Biochimica et Biophysica Acta (BBA) - General Subjects
69. Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin
    Roy S. Herbst, Nizar A. Mullani, Darren W. Davis, Kenneth R. Hess, David James McConkey, Chusilp Charnsangavej, Michael S. O’Reilly, Hyung-Woo Kim, Cheryl Hunt Baker, Jennifer S. Roach et al. · 2002 · Journal of Clinical Oncology
70. ‘Accidental’ anti-angiogenic drugs
    Robert S. Kerbel, Alicia Viloria‐Petit, Giannoula Lakka Klement, Janusz W. Rak · 2000 · European Journal of Cancer
71. What does physics have to do with cancer?
    Franziska Michor A, Jan Liphardt, Mauro Ferrari B, Jonathan Widom · 2011 · Nature reviews. Cancer
72. Calreticulin and Calreticulin Fragments Are Endothelial Cell Inhibitors That Suppress Tumor Growth
    Sandra E. Pike, Lei Yao, Joyce Setsuda, Karen D. Jones, Barry Cherney, Ettore Appella, Kazuyasu Sakaguchi, Hira Lal Nakhasi, Chintamani D. Atreya, Julie Teruya‐Feldstein et al. · 1999 · Blood
73. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1
    Yi Zhang, Eric C. Griffith, Julien Sage, Tyler Jacks, Jun O. Liu · 2000 · Proceedings of the National Academy of Sciences
74. Treatment of Canine Hemangiosarcoma: 2000 and Beyond
    Craig A. Clifford, Andrew J. Mackin, Carolyn J. Henry · 2000 · Journal of Veterinary Internal Medicine
75. Down-Regulation of Connective Tissue Growth Factor by Inhibition of Transforming Growth Factor β Blocks the Tumor–Stroma Cross-Talk and Tumor Progression in Hepatocellular Carcinoma
    Antonio Mazzocca, Emilia Fransvea, Francesco Dituri, L. Lupo, Salvatore Antonaci, Gianluigi Giannelli · 2009 · Hepatology
76. The Nc1/Endostatin Domain ofCaenorhabditis elegansType Xviii Collagen Affects Cell Migration and Axon Guidance
    Brian D. Ackley, Jennifer R. Crew, Harri P. Elamaa, Taina A. Pihlajaniemi, Calvin Jay Kuo, James M. Kramer · 2001 · The Journal of Cell Biology
77. Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors
    Matthew H. Kulke, Emily K. Bergsland, David P. Ryan, Peter C. Enzinger, Thomas James Lynch, Andrew Xiuxuan Zhu, Jeffrey A. Meyerhardt, John Victor Heymach, William E. Fogler, Carolyn Fowler Sidor et al. · 2006 · Journal of Clinical Oncology
78. Anginex, a designed peptide that inhibits angiogenesis
    Arjan W. Griffioen, Daisy W.J. van der Schaft, Annemarie F. Barendsz-Janson, Andrew COX, Harry A.J. Struijker-Boudier, Harry F P Hillen, Kevin H. Mayo · 2001 · Biochemical Journal
79. VEGF/VEGFR signalling as a target for inhibiting angiogenesis
    Alex S. Kiselyov, Konstantin V. Balakin, Sergey E. Tkachenko · 2006 · Expert Opinion on Investigational Drugs
80. Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells
    Maria Wartenberg, Fatma Dönmez, Frederike C. Ling, Helmut Acker, Jürgen Hescheler, Heinrich Sauer · 2001 · The FASEB Journal
81. Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy
    Jagat R. Kanwar, W.-P. Shen, Jagat R. Kanwar, Randy Berg, G W Krissansen · 2001 · JNCI Journal of the National Cancer Institute
82. VEGF blocking therapy in the treatment of cancer
    Julia Glade Bender, Jessica J. Kandel, Darrell J. Yamashiro · 2003 · Expert Opinion on Biological Therapy
83. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells
    Junichi Yoshii, Hitoshi Yoshiji, Shigeki Kuriyama, Yasuhide Ikenaka, Ryuichi Noguchi, Hirotsugu Okuda, Hirohisa Tsujinoue, Toshiya Nakatani, Hideki Kishida, Dai Nakae et al. · 2001 · International Journal of Cancer
84. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing
    Wilhelm Bloch, Katharina Huggel, Takako Sasaki, Richard Philip Grose, Philippe Bugnon, Klaus Addicks, Rupert Timpl, Sabine Werner · 2000 · The FASEB Journal
85. Selective targeting of cancer cells using synthetic peptides
    Mohsen Shadidi, Mouldy Sioud · 2003 · Drug Resistance Updates
86. Endostatin Inhibits Human Tongue Carcinoma Cell Invasion and Intravasation and Blocks the Activation of Matrix Metalloprotease-2, -9, and -13
    Pia Nyberg, Pia Heikkilä, Timo A. Sorsa, Jani Luostarinen, Ritva Heljäsvaara, Ulf‐Håkan Stenman, Taina A. Pihlajaniemi, Tuula Anneli Salo · 2003 · Journal of Biological Chemistry
87. Antiproliferative Effects of 1 ,25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells
    Ronald J. Bernardi, Candace S. Johnson, Ruth A. Modzelewski, Donald L. Trump · 2002 · Endocrinology
88. NG2 proteoglycan-binding peptides target tumor neovasculature.
    Michael A. Burg, Renata Pasqualini, Wadih Arap, Erkki I. Ruoslahti, William B. Stallcup · 1999 · PubMed
89. The antitumoral effect of endostatin and angiostatin is associated with a down‐regulation of vascular endothelial growth factor expression in tumor cells
    Amin Hajitou, Christine Grignet, Laetitia Devy, Sarah Berndt, Silvia Blacher, Christophe Deroanne, Khalid Bajou, T. Annie T. Fong, Yawen Chiang, Jean‐Michel Foidart et al. · 2002 · The FASEB Journal
90. In vivo small animal imaging: Current status and future prospects
    George C. Kagadis, George K. Loudos, Konstantinos H. Katsanos, Steve G. Langer, George C. Nikiforidis · 2010 · Medical Physics
91. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding
    Takako Kondo, Toshiro Ohta, Koichi Igura, Yukihiko Hara, Kazuhiko Kaji · 2002 · Cancer Letters
92. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
    Tina Cascone, Matthew H. Herynk, Li Xu, Zhiqiang Du, Humam N. Kadara, Monique B. Nilsson, Carol J. Oborn, Yun‐Yong Park, Baruch Erez, Jörg J. Jacoby et al. · 2011 · Journal of Clinical Investigation
93. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.
    Silvia Monestiroli, Patrizia Mancuso, Alessandra Burlini, Giancarlo Pruneri, Chiara Dell’Agnola, A Gobbi, Giovanni Martinelli, Francesco Bertolini · 2001 · PubMed
94. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo
    Yifan Zhai, Jian Ni, Gongwei Jiang, Jiamo Lu, Lily Xing, Clint Lincoln, Kenneth C. Carter, Fouad Janat, DIANE KOZAK, SIMIN XU et al. · 1999 · The FASEB Journal
95. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo
    Sara Gosk, Torben Moos, Claudia Gottstein, Gerd Bendas · 2008 · Biochimica et Biophysica Acta (BBA) - Biomembranes
96. Tumor angiogenesis – A potential target in cancer chemoprevention
    Tariq A. Bhat, Rana Pratap Singh · 2007 · Food and Chemical Toxicology
97. Targeting tumor vasculature with homing peptides from phage display
    Ruoslahti, Erkki · 2000 · Seminars in Cancer Biology
98. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
    Shoju Hiraga, Norio Arita, Takanori Ohnishi, Eiji Kohmura, Kazumi Yamamoto, Yuzuru Oku, Takuyu Taki, Masaharu Sato, Katsuyuki Aozasa, Toshiki Yoshimine · 1999 · Journal of neurosurgery
99. Angiogenic growth factors and endostatin in non‐Hodgkin's lymphoma
    Francesco Bertolini, Mara Paolucci, Fedro Alessandro Peccatori, Saverio Cinieri, Alberto Agazzi, Pier Francesco Ferrucci, Emilia Cocorocchio, Aron Goldhirsch, Giovanni Martinelli · 1999 · British Journal of Haematology
100. Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery
     Tong-Young Lee, Chin‐Tarng Lin, Szu-Yao Kuo, De-Kuan Chang, Han‐Chung Wu · 2007 · Cancer Research